Establishing a CYP3A5 genotype–guided tacrolimus dosing protocol in adult kidney transplant recipients
March 13, 2026
In this podcast, Dr. Amy Pasternak and Dr. Jamie Park discuss the AJHP Descriptive Report "Establishing a CYP3A5 genotype–guided tacrolimus dosing protocol in adult kidney transplant recipients” with host and AJHP Editor in Chief Dr. Daniel Cobaugh.
SPEAKERS
Amy Pasternak, Pharm.D., BCPS is a clinical associate professor and clinical pharmacy specialist in pharmacogenetics at the University of Michigan. Her research focuses on the discovery and validation of pharmacogenetic associations and evaluating the clinical impact of translating pharmacogenetics into patient care. As a clinical pharmacist, she works to implement pharmacogenetics into routine clinical workflows and works as part of the clinical pharmacogenetics consult service at Michigan Medicine.
Jeong (Jamie) Park, Pharm.D., MS, BCTXP, FCCP, FAST is a clinical professor and clinical pharmacy specialist in solid organ transplant at the University of Michigan. Her research focuses on the pharmacokinetics and patient outcomes in the solid organ transplant population. As a clinical pharmacist, she participates in the interprofessional care of kidney, liver, and pancreas transplant patients in both inpatient and outpatient settings.
Daniel J. Cobaugh, Pharm.D., FAACT, DABAT is the senior vice president of professional development and publishing at ASHP and the editor-in-chief of AJHP. He has served on the ASHP staff since 2002. He received his B.S. in Pharmacy from the University of Pittsburgh and his Doctor of Pharmacy from Duquesne University. Cobaugh completed an ASHP-accredited residency in hospital pharmacy at Mercy Hospital of Pittsburgh and a clinical toxicology fellowship at the Pittsburgh Poison Center. He practiced as pharmacist-clinical toxicologist and held faculty appointments at the University of Pittsburgh Medical Center and the University of Rochester Medical Center.
LISTEN ON
The information presented during the podcast reflects solely the opinions of the presenter. The information and materials are not, and are not intended as, a comprehensive source of drug information on this topic. The contents of the podcast have not been reviewed by ASHP, and should neither be interpreted as the official policies of ASHP, nor an endorsement of any product(s), nor should they be considered as a substitute for the professional judgment of the pharmacist or physician.
ADVERTISEMENT